Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
52 participants
INTERVENTIONAL
2012-08-31
2022-05-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The bug is classified into different groups based on its outer capsule (or shell), and this study will test a new vaccine to protect against group B meningococcus (MenB) disease, which is the most common type in the UK.
Vaccines are given to prepare the immune system to fight an infection. Vaccines work by stimulating the immune system to produce specialised proteins (called antibodies) and white blood cells designed to kill the bug later in life if needed.
Vaccines against other types of meningococcus have been developed and saved many lives. However MenB is different because its outer capsule does not stimulate the immune system very effectively. There is therefore no broadly effective vaccine against MenB disease.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MenPF-1 is a type of vaccine known as an Outer Membrane Vesicle (OMV) vaccine. This means that it has been produced from 'blebs' of the meningococcal bug's outer membrane, released by the meningococcus both during natural infection and in the laboratory. These outer membrane vesicles contain the PorA and FetA proteins, so can be used to make vaccines. The techniques used to produce the OMVs to make MenPF-1 are the same as those used in other very similar safe and effective vaccines. The MenB strain that the investigators use naturally produces PorA protein, and has been genetically modified to produce increased amounts of FetA for the OMV vaccine.
MenPF-1 contains:
* Many proteins, but especially PorA and FetA
* Aluminium, which is safe and commonly used in many vaccines to better activate the immune system
* Sugar and water for injection
It is worth noting that the vaccine product MenPF-1 is designed to work against MenB and, even if successful, would not protect against all forms of meningitis. Also, it is not a live vaccine and therefore cannot cause a meningitis infection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose vaccine arm
To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
MenPF-1.
A new vaccine against meningococcal disease.
High dose vaccine arm
To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
MenPF-1.
A new vaccine against meningococcal disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MenPF-1.
A new vaccine against meningococcal disease.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged between 18 and 50 years
* In good health as determined by medical history, physical examination and clinical judgment of the investigators
* (Females) Willing to use effective contraception (such as the oral contraceptive pill, contraceptive implant or barrier methods) from one month prior and for the duration of the study
* Able to attend the scheduled visits and to comply with all study procedures, including internet access for the recording of diary cards
* Willing to allow his or her General Practitioner and/or Consultant, if appropriate, to be notified of participation in the study
Exclusion Criteria
* Have any known or suspected impairment or alteration of immune function
* Study significant abnormalities on screening investigations at the discretion of an Investigator
* Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination
* Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination
* Scheduled procedures requiring general anaesthesia during the study
* Participant who is terminally ill
* Receipt of immunoglobulin or any blood product transfusion within 3 months of study start
* Participation in another research study involving an investigational product in the past 12 weeks, or are planning to do so within the 20 weeks of this study
* Previously having received a meningococcal B vaccine of any kind
* Previous occurrence of disease caused by N. meningitidis
* Inability, in the opinion of the Investigator, to comply with all study requirements
* Female participants who are pregnant, lactating or planning pregnancy during the course of the study
* Any other significant disease or disorder which, in the opinion of the Investigator, may
* Put the participants at risk because of participation in the study
* Influence the result of the study
* Impair the participant's ability to participate in the study
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wellcome Trust
OTHER
Norwegian Institute of Public Health
OTHER_GOV
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew J Pollard, PhD
Role: PRINCIPAL_INVESTIGATOR
Oxford Vaccine Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM)
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Green CA, Sande CJ, de Lara C, Thompson AJ, Silva-Reyes L, Napolitano F, Pierantoni A, Capone S, Vitelli A, Klenerman P, Pollard AJ. Humoral and cellular immunity to RSV in infants, children and adults. Vaccine. 2018 Oct 1;36(41):6183-6190. doi: 10.1016/j.vaccine.2018.08.056. Epub 2018 Aug 31.
Marsay L, Dold C, Green CA, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect. 2015 Sep;71(3):326-37. doi: 10.1016/j.jinf.2015.05.006. Epub 2015 May 15.
Related Links
Access external resources that provide additional context or updates about the study.
OVG website
MenPF-1 - A New Vaccine Against Meningococcal Disease
Humoral and cellular immunity to RSV in infants, children and adults
A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011/06
Identifier Type: -
Identifier Source: org_study_id